A drug used to treat advanced non-small cell lung cancer that has a mutated (changed) form of a gene called anaplastic lymphoma kinase (ALK). It is also being studied in the treatment of other types of cancer. Crizotinib blocks the protein made by the mutated ALK gene. Blocking this protein may stop the growth and spread of cancer cells. Crizotinib may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called MET tyrosine kinase inhibitor PF-02341066, PF-02341066, and Xalkori.